Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| pericyte | 23 studies | 37% ± 18% | |
| smooth muscle cell | 14 studies | 40% ± 25% | |
| endothelial cell | 11 studies | 23% ± 7% | |
| fibroblast | 9 studies | 30% ± 11% | |
| oligodendrocyte | 9 studies | 21% ± 6% | |
| endothelial cell of vascular tree | 8 studies | 40% ± 9% | |
| vein endothelial cell | 5 studies | 28% ± 13% | |
| myofibroblast cell | 3 studies | 32% ± 13% | |
| connective tissue cell | 3 studies | 33% ± 10% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| uterus | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 89% | 13577.49 | 407 / 459 | 94% | 14.85 | 1046 / 1118 |
| lung | 81% | 14646.22 | 466 / 578 | 75% | 8.56 | 865 / 1155 |
| stomach | 56% | 5669.77 | 201 / 359 | 82% | 9.75 | 234 / 286 |
| esophagus | 45% | 3467.41 | 655 / 1445 | 91% | 13.36 | 167 / 183 |
| thymus | 85% | 7374.96 | 553 / 653 | 42% | 3.98 | 256 / 605 |
| intestine | 49% | 4154.60 | 470 / 966 | 78% | 8.64 | 410 / 527 |
| ovary | 91% | 27382.71 | 163 / 180 | 32% | 2.26 | 138 / 430 |
| bladder | 52% | 3508.29 | 11 / 21 | 69% | 7.83 | 349 / 504 |
| brain | 40% | 1814.46 | 1059 / 2642 | 79% | 10.12 | 558 / 705 |
| adrenal gland | 50% | 3086.00 | 128 / 258 | 70% | 18.83 | 160 / 230 |
| kidney | 48% | 4205.20 | 43 / 89 | 69% | 18.75 | 620 / 901 |
| skin | 31% | 1105.84 | 562 / 1809 | 85% | 20.30 | 399 / 472 |
| pancreas | 20% | 571.35 | 64 / 328 | 94% | 18.05 | 167 / 178 |
| uterus | 55% | 3825.18 | 93 / 170 | 58% | 7.25 | 267 / 459 |
| prostate | 55% | 5804.44 | 135 / 245 | 41% | 4.78 | 205 / 502 |
| adipose | 94% | 22932.44 | 1132 / 1204 | 0% | 0 | 0 / 0 |
| liver | 23% | 944.65 | 52 / 226 | 54% | 4.07 | 221 / 406 |
| heart | 77% | 9404.07 | 660 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 65% | 7179.64 | 871 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 58% | 4.03 | 26 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 45% | 5.46 | 13 / 29 |
| muscle | 40% | 1858.80 | 324 / 803 | 0% | 0 | 0 / 0 |
| spleen | 15% | 388.46 | 35 / 241 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.05 | 1 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0001501 | Biological process | skeletal system development |
| GO_0030198 | Biological process | extracellular matrix organization |
| GO_0022617 | Biological process | extracellular matrix disassembly |
| GO_0006508 | Biological process | proteolysis |
| GO_0016607 | Cellular component | nuclear speck |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0031012 | Cellular component | extracellular matrix |
| GO_0002020 | Molecular function | protease binding |
| GO_0004222 | Molecular function | metalloendopeptidase activity |
| GO_0008233 | Molecular function | peptidase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0008270 | Molecular function | zinc ion binding |
| GO_0008237 | Molecular function | metallopeptidase activity |
| Gene name | ADAMTS4 |
| Protein name | A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAM-TS 4) (ADAM-TS4) (ADAMTS-4) (EC 3.4.24.82) (ADMP-1) (Aggrecanase-1) ADAM metallopeptidase with thrombospondin type 1 motif 4 |
| Synonyms | KIAA0688 UNQ769/PRO1563 |
| Description | FUNCTION: Cleaves aggrecan, a cartilage proteoglycan, and may be involved in its turnover. May play an important role in the destruction of aggrecan in arthritic diseases. Could also be a critical factor in the exacerbation of neurodegeneration in Alzheimer disease. Cleaves aggrecan at the '392-Glu-|-Ala-393' site. |
| Accessions | Q5VTW1 ENST00000367995.3 ENST00000367996.6 [O75173-1] O75173 |